Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (MOR208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

被引：0

作者：

Salles, Gilles ^{[1
,2
]}

Duell, Johannes ^{[3
]}

Gonzalez-Barca, Eva ^{[4
]}

Jurczak, Wojciech ^{[5
]}

Liberati, Anna Marina ^{[6
]}

de Vos, Sven ^{[7
]}

Nagy, Zsolt ^{[8
]}

Obr, Ales ^{[9
,10
]}

Gaidano, Gianluca ^{[11
]}

Abrisqueta, Pau ^{[12
]}

Kalakonda, Nagesh ^{[13
,14
]}

Andre, Marc ^{[15
]}

Dreyling, Martin ^{[16
]}

Menne, Tobias ^{[17
]}

Tournilhac, Olivier ^{[18
]}

Augustin, Marinela ^{[19
]}

Dirnberger-Hertweck, Maren ^{[20
]}

Weirather, Johannes ^{[20
]}

Ambarkhane, Sumeet ^{[20
]}

Maddocks, Kami J. ^{[21
]}

机构：

[1] Hosp Civils Lyon, Hematol, Lyon, France

[2] Univ Lyon, Lyon, France

[3] Univ Klin Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[4] Hosp Duran i Reynals, Inst Catala Oncol ICO, Dept Hematol, IDIBELL, Barcelona, Spain

[5] Maria Sklodowska Curie Natl Inst Oncol, Krakow, Poland

[6] Univ Perugia, Azienda Osped Santa Maria Terni, Terni, Italy

[7] Ronald Reagan UCLA Med Ctr, Dept Med, Santa Monica, CA USA

[8] Semmelweis Univ, Dept Internal Med 1, Budapest, Hungary

[9] Palacky Univ, Dept Hematooncol, Olomouc, Czech Republic

[10] Univ Hosp, Olomouc, Czech Republic

[11] Univ Piemonte Orientale Amedeo Avogadro, Div Hematol, Dept Translat Med, Novara, Italy

[12] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Hematol, Barcelona, Spain

[13] Univ Liverpool, Mol & Clin Canc Med, Liverpool, Merseyside, England

[14] Clatterbridge Canc Ctr, Liverpool, Merseyside, England

[15] Catholic Univ Louvain, Dept Haematol, CHU UCL Namur, Yvoir, Belgium

[16] Ludwig Maximilians Univ Munchen, Univ Hosp GroBhadern, Dept Med 3, Munich, Germany

[17] Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Dept Haematol, Newcastle Upon Tyne, Tyne & Wear, England

[18] CHU Estaing, Serv Hematol Clin & Therapie Cellulaire, Clermont Ferrand, France

[19] Univ Klin Paracelsus Med Privatuniv, Klin Innere Med 5, Nurnberg, Germany

[20] MorphoSys AG, Planegg, Germany

[21] Ohio State Univ, Dept Internal Med, Arthur G James Comprehens Canc Ctr, Wexner Med Ctr, Columbus, OH 43210 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷

关键词：

B cell lymphoma; DLBCL; CD19; immune therapy; ABCL; aggressive B-cell lymphoma;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-170

引用

页码：S267 / S268

页数：2

共 50 条

[1] Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Duell, J.
Gonzalez-Barca, E.
Augustin, M.
Jurczak, W.
Liberati, A. M.
de Vos, S.
Nagy, Z.
Obr, A.
Gaidano, G.
Abrisqueta, P.
Kalakonda, N.
Andre, M.
Menne, T.
Tournilhac, O.
Waltl, E. E.
Dirnberger-Hertweck, M.
Weirather, J.
Maddocks, K. J.
Ambarkhane, S.
Dreyling, M.
Salles, G.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 63 - 64
[2] Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Duell, Johannes
Maddocks, Kami J.
Gonzalez-Barca, Eva
Jurczak, Wojciech
Liberati, Anna Marina
de Vos, Sven
Nagy, Zsolt
Obr, Ales
Gaidano, Gianluca
Abrisqueta, Pau
Kalakonda, Nagesh
Andre, Marc
Dreyling, Martin
Menne, Tobias
Tournilhac, Olivier
Augustin, Marinela
Rosenwald, Andreas
Dirnberger-Hertweck, Maren
Weirather, Johannes
Ambarkhane, Sumeet
Salles, Gilles
HAEMATOLOGICA, 2021, 106 (09) : 2417 - 2426
[3] Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Maddocks, Kami J.
Duell, Johannes
Gonzalez-Barca, Eva
Jurczak, Wojciech
Liberati, Anna Marina
de Vos, Sven
Nagy, Zsolt
Obr, Ales
Gaidano, Gianluca
Abrisqueta, Pau
Andre, Marc
Dreyling, Martin
Menne, Tobias F.
Dirnberger-Hertweck, Maren
Weirather, Johannes
Ambarkhane, Sumeet
Salles, Gilles
BLOOD, 2020, 136
[4] Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Duell, Johannes
Maddocks, Kami J.
Gonzalez-Barca, Eva
Jurczak, Wojciech
Liberati, Anna Marina
de Vos, Sven
Nagy, Zsolt
Obr, Ales
Gaidano, Gianluca
Abrisqueta, Pau
Andre, Marc
Dreyling, Martin
Menne, Tobias F.
Dirnberger-Hertweck, Maren
Weirather, Johannes
Ambarkhane, Sumeet
Salles, Gilles A.
BLOOD, 2019, 134
[5] Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Dull, Johannes
Maddocks, Kami J.
Gonzalez-Barca, Eva
Jurczak, Wojciech
Liberati, Anna Marina
Obr, Ales
Gaidano, Gianluca
Abrisqueta, Pau
Andre, Marc
Dreyling, Martin H.
Menne, Tobias
Dirnberger-Hertweck, Maren
Weirather, Johannes
Ambarkhane, Sumeet Vijay
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study
Gonzalez-Barca, Eva
Duell, Johannes
Cavallo, Federica
Sancho, Juan-Manuel
Nagy, Zsolt
Abrisqueta, Pau
Panizo, Carlos
Augustin, Marinela
Weirather, Johannes
Ambarkhane, Sumeet
Maddocks, Kami J.
Kalakonda, Nagesh
Salles, Gilles
BLOOD, 2020, 136
[7] Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind
Salles, Gilles Andre
Duell, Johannes
Gonzalez-Barca, Eva
Jurczak, Wojciech
Liberati, Anna Marina
Nagy, Zsolt
Obr, Ales
Gaidano, Gianluca
Andre, Marc
Kalakonda, Nagesh
Dreyling, Martin
Zinzani, Pier Luigi
Dirnberger-Hertweck, Maren
Weirather, Johannes
Ambarkhane, Sumeet
Maddocks, Kami J.
BLOOD, 2018, 132
[8] Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind
Salles, Gilles Andre
Duell, Johannes
Gonzalez-Barca, Eva
Jurczak, Wojciech
Liberati, Anna Marina
Nagy, Zsolt
Papajik, Tomas
Gaidano, Gianluca
Andre, Marc
Kalakonda, Nagesh
Dreyling, Martin
Zinzani, Pier Luigi
Ambarkhane, Sumeet
Weirather, Johannes
Dirnberger-Hertweck, Maren
Maddocks, Kami J.
BLOOD, 2017, 130
[9] Five-year subgroup analysis of tafasitamab plus lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma
Duell, Johannes
Abrisqueta, Pau
Dreyling, Martin H.
Gaidano, Gianluca
Barca, Eva Gonzalez
Jurczak, Wojciech
Maddocks, Kami J.
Menne, Tobias
Tournilhac, Olivier
Bakuli, Abhishek
Amin, Aasim
Gurbanov, Konstantin
Salles, Gilles A.
Nagy, Zsolt
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Rodgers, Thomas
Zinzani, Pier Luigi
Marino, Dario
Frezzato, Maurizio
Barbui, Anna Maria
Castellino, Claudia
Meli, Erika
Conconi, Annarita
Cascavilla, Nicola
Cavallo, Federica
Fowler, Nathan H.
Feinberg, Bruce
Tillmanns, Sascha
Parche, Stephan
Fingerle-Rowson, Gunter
Winderlich, Mark
Ambarkhane, Sumeet
Salles, Gilles
Nowakowski, Grzegorz
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S265 - S266

← 1 2 3 4 5 →